Voyager Therapeutics, Inc.
No SEC Form 4 filings for $VYGR in the last 30 days.
See all $VYGR insider activity →Viking Therapeutics raised ~$547.8M in net proceeds from a $575M offering of common stock and convertible notes. The offering included 9,035,714 shares at $35.00 each and $258.75M in notes due 2032. Underwriters exercised options for additional shares and notes.
Viking Therapeutics priced a $500 million upsized offering of common shares and convertible senior notes due in 2032. The company's stock is currently trading at $41.65, up 1.96% in pre-market. This follows a previous announcement of plans for the offering.
Voyager Technologies' shares dropped 7.8% in after-hours trading after announcing a $350 million convertible senior notes offering. The company plans to use proceeds for capped call transactions, general corporate purposes, and expansion. Shares closed at $37.53, up 44% year-to-date.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning VYGR (Voyager Therapeutics, Inc.). Coverage has been balanced: 3 bullish, 0 neutral, and 3 bearish.
Recent VYGR coverage spans corporate actions, market movers and earnings.
The sizable equity and debt issuance will likely dilute existing shareholders and increase leverage.
The capital raise provides significant funding and may dilute existing shareholders.
The capital raise may dilute equity and increase debt, pressuring the stock in the short term.
Strong trial results suggest VK2735 could capture market share from Novo Nordisk and Eli Lilly, likely driving further price appreciation.
Street expectations shift toward higher 2026 revenue but also higher per-share losses, keeping the consensus price target unchanged.
AlphAI scores every news story that mentions VYGR with an AI model for sentiment and relevance, and aggregates insider trades from Voyager Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Viking Therapeutics raised ~$547.8M in net proceeds from a $575M offering of common stock and convertible notes. The offering included 9,035,714 shares at $35.00 each and $258.75M in notes due 2032. Underwriters exercised options for additional shares and notes.
1 min readViking Therapeutics priced a $500 million upsized offering of common shares and convertible senior notes due in 2032. The company's stock is currently trading at $41.65, up 1.96% in pre-market. This follows a previous announcement of plans for the offering.
1 min readVoyager Technologies' shares dropped 7.8% in after-hours trading after announcing a $350 million convertible senior notes offering. The company plans to use proceeds for capped call transactions, general corporate purposes, and expansion. Shares closed at $37.53, up 44% year-to-date.
2 min readViking Therapeutics' stock rose 40% premarket after trial data showed its obesity drug VK2735 maintained weight loss with less frequent dosing. Patients kept 97% of weight loss on biweekly dosing and 90% on monthly dosing. Analysts highlight potential clinical advantages. The company aims to compete with Novo Nordisk and Eli Lilly in a market projected to reach $100B by 2030.
1 min readVoyager Therapeutics (NASDAQ:VYGR) reported second-quarter results. Shares rose 7.9% to $3.27. Revenues were 31% below analyst predictions, while losses of $0.40 per share were 20% smaller than expected. Analysts now forecast 2026 revenue of $46.0m (up from $39.3m) and losses of $1.87 per share, with the consensus price target unchanged at $14.89.
5 min readVoyager Therapeutics, Inc. (VYGR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Voyager Reports Second Quarter 2026 Financial and Operating Results - VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 - - Ended Q2 2026 with cash position of $149 million, runway into 2028 - LEXINGTON, Mass., August 6, 2026 -- Voyager Therape
6 min readAhead of Q2 earnings, Morgan Stanley kept a constructive view on aerospace and defense, citing resilient commercial demand, improving aircraft production, and durable aftermarket needs. It noted Boeing 737 MAX at 47 aircraft per month. For defense, it argued a $1.1T FY2027 base budget is underestimated. It downgraded Loar and TransDigm, cut CAE and Voyager, and adjusted price targets for multiple firms.
4 min readOn Jim Cramer’s “Mad Money” (June 30), he told a 23-year-old caller to buy Voyager Therapeutics (NASDAQ:VYGR) based on a long time horizon, noting the company is still unprofitable. Voyager has Q1 FY26 revenue of $2.59M (vs $8.79M consensus) and net loss of $27.94M; cash $171.66M. Analysts rate VYGR 11 Buys with ~$14.89–$15 average targets.
6 min readBenzinga reports analyst actions and stock moves for several companies. Bernstein initiated GE Vernova coverage (Outperform) with a $1,206 target. Ultra Clean was reiterated/raised by Oppenheimer to $115; shares rose 9.1%. Voyager Technologies rose 6.9% after FDA clearance for VY1706. TE Connectivity target raised to $230; Symbotic fell; Enphase rose after joining Open Compute Project.
6 min readVoyager Therapeutics, Inc. (VYGR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false --12-31 0001640266 0001640266 2026-06-09 2026-06-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date
2 min read
